Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, controlled phase 2/3 pivotal trial of bertilimumab in bullous pemphigoid

Next Previous
X
Search
Trial Profile

A randomized, controlled phase 2/3 pivotal trial of bertilimumab in bullous pemphigoid

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 30 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bertilimumab (Primary)
  • Indications Bullous pemphigoid
  • Focus Registrational; Therapeutic Use
  • Sponsors Immune Pharmaceuticals Inc

    • Most Recent Events

    • 23 May 2018 According to Immune Pharmaceuticals media release, The Company is preparing for meetings with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) later this year to discuss the planned phase 2/3 study as well as important manufacturing plans
    • 15 May 2018 According to Immune Pharmaceuticals media release, the company is planning to discuss this trial with the FDA later in 2018.
    • 22 Feb 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top